Crossmark

Treatment of HCV-infected patients with advanced kidney disease

Crossref DOI link: https://doi.org/10.1038/nrneph.2017.161

Published Online: 2017-11-27

Published Print: 2018-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ladino, Marco

Roth, David
License Information

Text and Data Mining valid from 2017-11-27
More Information

Article History

First Online: 27 November 2017

Competing interests

: M.L. declares no competing interests. D.R. is a consultant and is on the Scientific Advisory Boards for Merck & Co. and AbbVie.